July 26, 2016 2:01 AM ET


Company Overview of Dezima Pharma B.V.

Company Overview

Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.

Gooimeer 2-35

Naarden,  1411 DC


Founded in 2012


31 35 699 3000


31 35 699 3001

Key Executives for Dezima Pharma B.V.

Chief Executive Officer
Founder and Chairman of Scientific Advisory Board
Age: 62
Compensation as of Fiscal Year 2016.

Dezima Pharma B.V. Key Developments

Dezima Pharma B.V. Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects with Isolated, Elevated Lipoprotein(a) Levels

Dezima Pharma B.V. announced the complete enrolment of a study with TA-8995 in asymptomatic subjects with isolated, severely elevated Lipoprotein(a) (Lp(a)), which was initiated in September of 2014. The aim of this study, that enrolled 42 male and female subjects from the Copenhagen General Population Study database, is to investigate the Lp(a) lowering effects of TA-8995 (DEZ-001), a best-in-class CETP inhibitor. The subjects have been randomised to one of two different doses of TA-8995 or placebo and will be treated for 12 weeks. The Lp(a) pilot study is being conducted at the Herlev Hospital, Copenhagen University Hospital in Denmark. Lp(a) is an independent major risk factor for cardiovascular disease and aortic valve stenosis. In previous phase 1 studies in healthy volunteers with normal baseline Lp(a) levels, as well as in the phase 2b TULIP study, TA-8995 has shown a potent effect on Lp(a) plasma levels.

Dezima Pharma Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia

Dezima Pharma announced that it has received very positive results in its Phase 2b TULIP clinical trial, a double blind, placebo controlled, Phase 2b dose ranging study of TA-8995 (DEZ-001), as monotherapy and in combination with statins for treating dyslipidemia. The TULIP (TA-8995: its Use in patients with mild dysLIPidemia) study was conducted in specialized cardiovascular centres across Denmark and the Netherlands. A total of 364 patients were randomised into nine cohorts; a placebo, TA-8995 alone at different doses, or in combination with different statins. The study investigated the effects of TA-8995 on a wide range of established cardiovascular disease (CVD) biomarkers over a three months' dosing period. The results showed dramatic effects on the primary endpoint, which was a composite of changes in lowering LDL-C and raising HDL-C, as well as strong and clinically relevant effects on other parameters including cholesterol efflux and Lipoprotein(a) (Lp(a)). There were no safety or tolerability issues identified or any pharmacokinetic concerns about potential accumulation of the drug.

Similar Private Companies By Industry

Company Name Region
ACS Biomarker B.V. Europe
Aduro Biotech Europe Europe
Agventure Exploitatie BV Europe
Alloksys Life Sciences BV Europe
AM-Pharma B.V. Europe

Recent Private Companies Transactions

September 16, 2015

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Dezima Pharma B.V., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.